Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
